Novo Nordisk A/S: Monlunabant phase 2a trial in obesity …
WEB15 hours ago · Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse ...
News Details - novonordisk.com
WEB1 day ago · Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed. Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc. announced in ...
European Drug Agency Supports Novo Nordisk's Blockbuster …
WEB16 hours ago · The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide 2.4 ...
News Details - novonordisk.com
WEB2 days ago · News & media; Patient help; Healthcare professionals ... is the first obesity medication to receive a positive opinion recommending a label update that reflects reduced symptoms and ... scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 69,000 people in …
News Details - Novo Nordisk
WEBMay 22, 2023 · Novo Nordisk A/S: Oral semaglutide 50 mg achieved 15.1% weight loss (17.4% if all people adhered to treatment) in adults with obesity or overweight in the OASIS 1 trial. Bagsværd, Denmark, 22 May 2023 – Novo Nordisk today announced headline results from OASIS 1, a phase 3a trial in the global OASIS programme. OASIS 1 is a 68-week, efficacy ...
Wegovy Cuts Risk of Heart Problems, Novo Nordisk Trial Says
WEBAug 8, 2023 · A new obesity drug, Wegovy, slashed the risk of serious heart problems by 20 percent in a large trial, the drug’s maker said on Tuesday, a finding that could challenge the perception of weight...
Novo Nordisk receives FDA approval for Wegovy™ to treat …
WEBPLAINSBORO, N.J., June 4, 2021 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for Wegovy ™ (semaglutide)...
Novo Nordisk’s Wegovy Gets EU Backing to Treat Obesity …
WEB1 day ago · Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure in obese patients. The Danish pharmaceutical giant said late Thursday ...
Novo Nordisk shares drop nearly 5% on disappointing obesity …
WEB14 hours ago · Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.
News details - Novo Nordisk
WEBMar 8, 2024 · Novo Nordisk's commitment to the obesity and cardiovascular community is a long-term one, and we are investing significantly to build capacity to meet increasing demand. Please visit WegovySupply.com for the latest information.